Wayland Group Corp Aktie Canadian Securities Exchange
Aktien
CA5667241007
Pharmazeutika
Umsatz 2016 | 4.06 5.57 3.69 | Umsatz 2017 | 3.22 4.43 2.93 | Marktwert | 203 Mio. 279 Mio. 185 Mio. |
---|---|---|---|---|---|
Nettoergebnis 2016 | -8 Mio. -10.98 Mio. -7.26 Mio. | Nettoergebnis 2017 | -67 Mio. -92 Mio. -60.84 Mio. | EV / Sales 2016 * | - |
Nettoschuld 2016 | 9.13 12.53 8.29 | Nettoliquidität 2017 | 0.42 0.57 0.38 | EV / Sales 2017 | 63’046’727 x |
KGV 2016 * |
-
| KGV 2017 |
-2.13
x | Beschäftigte | - |
Rendite 2016 * |
-
| Rendite 2017 |
-
| Streubesitz | 100% |
Manager | Titel | Alter | Seit |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
% 1. Jan. | Kap. | |
---|---|---|
+43.96% | 6.32 Mrd. | |
-15.56% | 4.49 Mrd. | |
-6.52% | 3.3 Mrd. | |
+5.47% | 3.19 Mrd. | |
-0.76% | 2.6 Mrd. | |
+56.34% | 2.05 Mrd. | |
-4.11% | 1.77 Mrd. | |
+2.93% | 1.7 Mrd. | |
-8.02% | 1.63 Mrd. |